Danirixin

Drug Profile

Danirixin

Alternative Names: 1325756; GSK-1325756; GSK-1325756H; GSK1325756B

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antivirals; Piperidines; Sulfones
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Influenza virus infections

Most Recent Events

  • 21 Aug 2017 GlaxoSmithKline terminates a phase II trial in Influenza virus infections (Combination therapy) in USA, France, Korea, Netherlands, Romania, Russia, Spain and Sweden due to lack of enrolment (NCT02927431) (EudraCT2016-002512-40)
  • 11 Aug 2017 GlaxoSmithKline plans a phase II trial for Chronic obstructive pulmonary disease (In adults, In the elderly) in September 2017 (NCT03250689)
  • 31 Jul 2017 GlaxoSmithKline completes a phase I trial in Chronic obstructive pulmonary disease (In volunteers, In the elderly) (PO) in Japan (NCT03136380)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top